---
schema_version: "secwatch.filing_event.v1"
accession: "0001826667-25-000071"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:39:00.430597+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TriSalus Life Sciences appoints David Patience as CFO; James Young resigns

## Summary
- CFO James Young resigned for personal reasons effective May 30, 2025; receives six months salary and continued equity vesting through May 2026.
- David Patience appointed CFO effective July 1, 2025; base salary $450,000, sign-on bonus $159,000, eligible for 50% annual bonus and 1% stock option grant.
- Dan Giordano, VP of Finance, serves as acting CFO during transition; Young remains available for orderly handover.
- Patience previously CFO at Accelerate Diagnostics; also held roles at Morgan Stanley, Continental Advisors, and Nuveen Investments.

## SEC filing metadata
- accession: 0001826667-25-000071
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000071/0001826667-25-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000071/tlsi-20250523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001826667-25-000071
- JSON: https://secwatch.observer/filing/0001826667-25-000071.json
- Plain text: https://secwatch.observer/filing/0001826667-25-000071.txt

## Key facts
- Executive change
  James Young resigned as Chief Financial Officer at TriSalus Life Sciences, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Mr. Young resigned from the Company for personal reasons, effective May 30, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000071/0001826667-25-000071-index.htm
- Executive change
  David Patience was appointed as Chief Financial Officer at TriSalus Life Sciences, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 27, 2025, the Company entered into an offer letter with David Patience for the position of Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000071/0001826667-25-000071-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.